Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
Michael C. Heinrich(VA Portland Health Care System), Jonathan A. Fletcher(Borders General Hospital), Monica M. Bertagnolli(National Institutes of Health), Christopher L. Corless(Oregon Health & Science University), Kouros Owzar(Duke University), Charles D. Blanke(SWOG Cancer Research Network), Christopher W. Ryan(Oregon Health & Science University), Robert S. Benjamin(The University of Texas MD Anderson Cancer Center), Christopher D.�M. Fletcher(Brigham and Women's Hospital), George D. Demetri(Dana-Farber Cancer Institute), Margaret von Mehren(Temple University Health System), Vivien Bramwell(Western University), Donna Hollis(University of North Carolina at Chapel Hill), Ernest C. Borden(Cleveland Clinic), Cathryn Rankin(Cleveland Clinic)
Cited by 655
Related Papers
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k